The Strategic Role of Biomarkers in Drug Discovery and Clinical Trials Every decision in drug development carries weight. The ...

BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...

Ibex’s high-performance AI platform—already deployed across more than 50 health systems worldwide and used in collaboration ...

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

Mass spectrometry (MS)-based proteomic biomarker discovery pipeline commonly begins with large-scale profiling techniques detecting thousands of candidate biomarkers. Efficiently triaging these ...

Researchers from Critical Path Institute's ® (C-Path) Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for detecting liver injury, ...

Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson's disease SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...